My Bibliography

select

Schweppe RE, Frazer-Abel AA, Gutierrez-Hartmann A, Bradford AP. Functional components of fibroblast growth factor (FGF) signal transduction in pituitary cells. Identification of FGF response elements in the prolactin gene. J Biol Chem. 1997 Dec 5;272(49):30852-9. doi: 10.1074/jbc.272.49.30852. PubMed PMID: 9388230.

select

Johnson TK, Schweppe RE, Septer J, Lewis RE. Phosphorylation of B-Myb regulates its transactivation potential and DNA binding. J Biol Chem. 1999 Dec 17;274(51):36741-9. doi: 10.1074/jbc.274.51.36741. PubMed PMID: 10593981.

select

Schweppe RE, Gutierrez-Hartmann A. Pituitary Ets-1 and GABP bind to the growth factor regulatory sites of the rat prolactin promoter. Nucleic Acids Res. 2001 Mar 1;29(5):1251-60. doi: 10.1093/nar/29.5.1251. PubMed PMID: 11222776; PubMed Central PMCID: PMC29733.

select

Jackson TA, Schweppe RE, Koterwas DM, Bradford AP. Fibroblast growth factor activation of the rat PRL promoter is mediated by PKCdelta. Mol Endocrinol. 2001 Sep;15(9):1517-28. doi: 10.1210/mend.15.9.0683. PubMed PMID: 11518800.

select

Vaish NK, Dong F, Andrews L, Schweppe RE, Ahn NG, Blatt L, Seiwert SD. Monitoring post-translational modification of proteins with allosteric ribozymes. Nat Biotechnol. 2002 Aug;20(8):810-5. doi: 10.1038/nbt719. Epub 2002 Jul 15. PubMed PMID: 12118241.

select

Tentler JJ, Bradford AP, Schweppe RE, Gutierrez-Hartmann A. Selective repression of rat prolactin gene by stable expression of dominant-negative Ets in GH4 pituitary cells. Endocrine. 2003 Feb-Mar;20(1-2):3-12. doi: 10.1385/ENDO:20:1-2:3. PubMed PMID: 12668863.

select

Schweppe RE, Melton AA, Brodsky KS, Aveline LD, Resing KA, Ahn NG, Gutierrez-Hartmann A. Purification and mass spectrometric identification of GA-binding protein (GABP) as the functional pituitary Ets factor binding to the basal transcription element of the prolactin promoter. J Biol Chem. 2003 May 9;278(19):16863-72. doi: 10.1074/jbc.M213063200. Epub 2003 Mar 4. PubMed PMID: 12618435.

select

Schweppe RE, Haydon CE, Lewis TS, Resing KA, Ahn NG. The characterization of protein post-translational modifications by mass spectrometry. Acc Chem Res. 2003 Jun;36(6):453-61. doi: 10.1021/ar020143l. Review. PubMed PMID: 12809532.

select

Schweppe RE, Cheung TH, Ahn NG. Global gene expression analysis of ERK5 and ERK1/2 signaling reveals a role for HIF-1 in ERK5-mediated responses. J Biol Chem. 2006 Jul 28;281(30):20993-21003. doi: 10.1074/jbc.M604208200. Epub 2006 May 30. PubMed PMID: 16735500.

select

Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41. doi: 10.1210/jc.2008-1102. Epub 2008 Aug 19. PubMed PMID: 18713817; PubMed Central PMCID: PMC2582569.

select

Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, Litman ES, Croy CH, Meyer-Arendt K, Miranda JG, Brown RA, Witze ES, Schweppe RE, Resing KA, Ahn NG. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell. 2009 Apr 10;34(1):115-31. doi: 10.1016/j.molcel.2009.03.007. PubMed PMID: 19362540; PubMed Central PMCID: PMC2735263.

select

Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009 Jun;94(6):2199-203. doi: 10.1210/jc.2008-2511. Epub 2009 Mar 17. PubMed PMID: 19293266; PubMed Central PMCID: PMC2690419.

select

Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid. 2009 Aug;19(8):825-35. doi: 10.1089/thy.2008.0362. PubMed PMID: 19500021; PubMed Central PMCID: PMC2857444.

select

Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G. Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells. Endocr Rev. 2009 Dec 1;30(7):932. doi: 10.1210/edrv.30.7.9986. PubMed PMID: 28199516.

select

Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab. 2010 Jan;95(1):450-5. doi: 10.1210/jc.2009-0373. Epub 2009 Oct 30. PubMed PMID: 19880792.

select

Bauerle KT, Schweppe RE, Haugen BR. Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer. 2010 May 21;9:117. doi: 10.1186/1476-4598-9-117. PubMed PMID: 20492683; PubMed Central PMCID: PMC2887796.

select

Schweppe RE, Haugen BR. Thyroid targeted Kras(G12D)/Pten(-/-) mice and their cell lines: new tools to study thyroid cancer biology. Thyroid. 2011 Sep;21(9):941-4. doi: 10.1089/thy.2011.2109.ed. PubMed PMID: 21877921.

select

Wood WM, Sharma V, Bauerle KT, Pike LA, Zhou Q, Fretwell DL, Schweppe RE, Haugen BR. PPARγ Promotes Growth and Invasion of Thyroid Cancer Cells. PPAR Res. 2011;2011:171765. doi: 10.1155/2011/171765. Epub 2011 Dec 12. PubMed PMID: 22194735; PubMed Central PMCID: PMC3236353.

select

Schweppe RE. Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets. Front Endocrinol (Lausanne). 2012;3:81. doi: 10.3389/fendo.2012.00081. eCollection 2012. PubMed PMID: 22723793; PubMed Central PMCID: PMC3378072.

select

Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012 Jul 1;18(13):3580-91. doi: 10.1158/1078-0432.CCR-11-3359. Epub 2012 May 14. PubMed PMID: 22586301; PubMed Central PMCID: PMC3931551.

select

Schweppe RE. Thyroid cancer cell line misidentification: an update. J Clin Endocrinol Metab. 2013 Mar;98(3):956-7. doi: 10.1210/jc.2012-4182. PubMed PMID: 23472230; PubMed Central PMCID: PMC3590476.

select

Plantinga TS, Heinhuis B, Gerrits D, Netea MG, Joosten LA, Hermus AR, Oyen WJ, Schweppe RE, Haugen BR, Boerman OC, Smit JW, Netea-Maier RT. mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2014 Jul;99(7):E1368-75. doi: 10.1210/jc.2014-1171. Epub 2014 Apr 8. PubMed PMID: 24712572; PubMed Central PMCID: PMC5393487.

select

Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood WM, Haugen BR. Nuclear factor κB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab. 2014 Aug;99(8):E1436-44. doi: 10.1210/jc.2013-3636. Epub 2014 Apr 23. PubMed PMID: 24758177; PubMed Central PMCID: PMC4121024.

select

Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL. Development and characterization of six new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2015 Feb;100(2):E243-52. doi: 10.1210/jc.2014-2624. Epub 2014 Nov 26. PubMed PMID: 25427145; PubMed Central PMCID: PMC4318904.

select

Chatterji T, Varkaris AS, Parikh NU, Song JH, Cheng CJ, Schweppe RE, Alexander S, Davis JW, Troncoso P, Friedl P, Kuang J, Lin SH, Gallick GE. Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells. Oncotarget. 2015 Apr 30;6(12):10175-94. doi: 10.18632/oncotarget.3391. PubMed PMID: 25868388; PubMed Central PMCID: PMC4496348.

select

Morrison JA, Pike LA, Lund G, Zhou Q, Kessler BE, Bauerle KT, Sams SB, Haugen BR, Schweppe RE. Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models. Horm Cancer. 2015 Jun;6(2-3):87-99. doi: 10.1007/s12672-015-0219-0. Epub 2015 Mar 24. PubMed PMID: 25800363; PubMed Central PMCID: PMC4414894.

select

Beadnell TC, Mishall KM, Zhou Q, Riffert SM, Wuensch KE, Kessler BE, Corpuz ML, Jing X, Kim J, Wang G, Tan AC, Schweppe RE. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer. Mol Cancer Ther. 2016 Aug;15(8):1952-63. doi: 10.1158/1535-7163.MCT-15-0702. Epub 2016 May 24. PubMed PMID: 27222538; PubMed Central PMCID: PMC4975658.

select

Pozdeyev N, Yoo M, Mackie R, Schweppe RE, Tan AC, Haugen BR. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. Oncotarget. 2016 Aug 9;7(32):51619-51625. doi: 10.18632/oncotarget.10010. PubMed PMID: 27322211; PubMed Central PMCID: PMC5239501.

select

Kessler BE, Sharma V, Zhou Q, Jing X, Pike LA, Kerege AA, Sams SB, Schweppe RE. FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes. Mol Cancer Res. 2016 Sep;14(9):869-82. doi: 10.1158/1541-7786.MCR-16-0007. Epub 2016 Jun 3. PubMed PMID: 27259715; PubMed Central PMCID: PMC5025360.

select

Mishall KM, Beadnell TC, Kuenzi BM, Klimczak DM, Superti-Furga G, Rix U, Schweppe RE. Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer. Oncotarget. 2017 Nov 28;8(61):103014-103031. doi: 10.18632/oncotarget.20488. eCollection 2017 Nov 28. PubMed PMID: 29262541; PubMed Central PMCID: PMC5732707.

select

Beadnell TC, Nassar KW, Rose MM, Clark EG, Danysh BP, Hofmann MC, Pozdeyev N, Schweppe RE. Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis. 2018 Feb 28;7(2):23. doi: 10.1038/s41389-017-0015-5. PubMed PMID: 29487290; PubMed Central PMCID: PMC5833015.

select

Kiseljak-Vassiliades K, Zhang Y, Bagby SM, Kar A, Pozdeyev N, Xu M, Gowan K, Sharma V, Raeburn CD, Albuja-Cruz M, Jones KL, Fishbein L, Schweppe RE, Somerset H, Pitts TM, Leong S, Wierman ME. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer. 2018 Apr;25(4):437-451. doi: 10.1530/ERC-17-0447. Epub 2018 Jan 25. PubMed PMID: 29371329; PubMed Central PMCID: PMC5831504.

select

Oweida A, Phan A, Vancourt B, Robin T, Hararah MK, Bhatia S, Milner D, Lennon S, Pike L, Raben D, Haugen B, Pozdeyev N, Schweppe R, Karam SD. Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid. 2018 Jun;28(6):739-747. doi: 10.1089/thy.2017.0706. PubMed PMID: 29774792; PubMed Central PMCID: PMC6040202.

select

Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018 Jul 1;24(13):3059-3068. doi: 10.1158/1078-0432.CCR-18-0373. Epub 2018 Apr 3. PubMed PMID: 29615459; PubMed Central PMCID: PMC6030480.

select

Rosenthal MS, Angelos P, Schweppe RE. Research ethics dilemmas in thyroid disease. Curr Opin Endocrinol Diabetes Obes. 2018 Oct;25(5):335-340. doi: 10.1097/MED.0000000000000429. Review. PubMed PMID: 30095478.

select

Kessler BE, Mishall KM, Kellett MD, Clark EG, Pugazhenthi U, Pozdeyev N, Kim J, Tan AC, Schweppe RE. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Oncogene. 2019 Apr;38(14):2565-2579. doi: 10.1038/s41388-018-0617-1. Epub 2018 Dec 10. PubMed PMID: 30531837; PubMed Central PMCID: PMC6450711.

select

Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Mol Cancer Res. 2019 May;17(5):1036-1048. doi: 10.1158/1541-7786.MCR-18-1026. Epub 2019 Feb 7. PubMed PMID: 30733375; PubMed Central PMCID: PMC6711777.

select

Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. Clin Cancer Res. 2019 May 15;25(10):3141-3151. doi: 10.1158/1078-0432.CCR-18-2953. Epub 2019 Feb 8. PubMed PMID: 30737244; PubMed Central PMCID: PMC6522280.

select

Capes-Davis A, Bairoch A, Barrett T, Burnett EC, Dirks WG, Hall EM, Healy L, Kniss DA, Korch C, Liu Y, Neve RM, Nims RW, Parodi B, Schweppe RE, Storts DR, Tian F. Cell Lines as Biological Models: Practical Steps for More Reliable Research. Chem Res Toxicol. 2019 Sep 16;32(9):1733-1736. doi: 10.1021/acs.chemrestox.9b00215. Epub 2019 Jun 15. PubMed PMID: 31203605; PubMed Central PMCID: PMC6748863.

select

Landa I, Pozdeyev N, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Genetics of Human Thyroid Cancer Cell Lines-Response. Clin Cancer Res. 2019 Nov 15;25(22):6883-6884. doi: 10.1158/1078-0432.CCR-19-2531. PubMed PMID: 31732665; PubMed Central PMCID: PMC7396876.

select

Pozdeyev N, Rose MM, Bowles DW, Schweppe RE. Molecular therapeutics for anaplastic thyroid cancer. Semin Cancer Biol. 2020 Apr;61:23-29. doi: 10.1016/j.semcancer.2020.01.005. Epub 2020 Jan 25. PubMed PMID: 31991166; PubMed Central PMCID: PMC7117889.

select

Hicks HM, McKenna LR, Espinoza VL, Pozdeyev N, Pike LA, Sams SB, LaBarbera D, Reigan P, Raeburn CD, E Schweppe R. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Mol Carcinog. 2021 Mar;60(3):201-212. doi: 10.1002/mc.23284. PubMed PMID: 33595872.

select

Nassar KW, Hintzsche JD, Bagby SM, Espinoza V, Langouët-Astrié C, Amato CM, Chimed TS, Fujita M, Robinson W, Tan AC, Schweppe RE. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. Mol Cancer Ther. 2021 Oct;20(10):2049-2060. doi: 10.1158/1535-7163.MCT-20-1126. Epub 2021 Aug 10. PubMed PMID: 34376578; PubMed Central PMCID: PMC9768695.